Shutai God: STSP-902 Eye Drops Phase I Clinical Study Summary Report

Shutai Shen announced that it has recently obtained the Phase I clinical study summary report of STSP-902 eye drops. STSP-902 eye drops are used for the treatment of neurotrophic keratitis. The company submitted a clinical trial application in April 2024, was approved in July 2024, and completed the first dose to the subject in October 2024. The research results show that both single and multiple doses of STSP-902 eye drops are generally safe and well tolerated in healthy subjects, with no evidence of systemic drug exposure or immunogenicity. Pharmacokinetic results show that the experimental drug can still be detected in tear samples 6 hours after a single dose. These study results support further clinical trials in patients with neurotrophic keratitis.